Loading...
XNAS
NAOV
Market cap3mUSD
Dec 05, Last price  
4.15USD
1D
1.47%
1Q
-20.12%
Jan 2017
-30.37%
IPO
18.57%
Name

Nanovibronix Inc

Chart & Performance

D1W1MN
XNAS:NAOV chart
P/E
P/S
1.29
EPS
Div Yield, %
Shrs. gr., 5y
-4.90%
Rev. gr., 5y
37.00%
Revenues
3m
+12.05%
94,000166,000211,000203,000147,000229,000239,000318,000530,000623,0001,695,000752,0002,283,0002,558,000
Net income
-4m
L-0.16%
-723,000-1,275,000-1,989,000-2,647,000-2,884,000-2,831,000-4,965,000-4,154,000-5,794,000-4,326,000-14,282,000-5,448,000-3,711,000-3,705,000
CFO
-3m
L-30.15%
-547,000-787,000-602,000-900,000-1,480,000-1,533,000-2,182,000-3,550,000-3,874,000-3,391,000-4,367,000-7,035,000-3,602,000-2,516,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
IPO date
Apr 24, 2015
Employees
9
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT